[Efficiency of taliton in treatment of ischemic cardiomyopathy].
The aim of investigation was to assess efficiency and safety of the lypophilic beta-adrenobloker taliton (carvedilol) in patients with ischemic cardiomiopathy. 20 patients with ischemic cardiomiopathy entered an open trial, mean age 59 years. All patients received basic therapy (ACE-inhibitors, diuretics, aspirin) and taliton. Starting dose of taliton was 3,125 mg twice daily. Dose increased with 2-weekly interval till target dose 25 mg twice daily. Duration of investigation was 6 months. The efficacy of treatment was assessed by the clinical examination, the results of echocardiography and 24 h monitoring of ECG. After treatment with taliton for 6 months increased ejection fraction, left ventricle sizes and volumes decreased, on 24 monitoring of ECG ST depression decreased. There was no side effects of taliton.